Cell-free self-DNA or RNA may induce an immune response by activating specific sensing receptors. During pregnancy, placental nucleic acids present in the maternal circulation further activate these receptors due to the presence of unmethylated CpG islands. A higher concentration of cell-free foetal DNA is associated with pregnancy complications and a higher risk for foetal rejection. Cell-free foetal DNA originates from placental trophoblasts. It appears in different forms: free, bound to histones in nucleosomes, in neutrophil extracellular traps (NETs) and in extracellular vesicles (EVs). In several pregnancy complications, cell-free foetal DNA triggers the production of proinflammatory cytokines, and this production results in a cellular and humoral immune response. This review discusses preeclampsia, systemic lupus erythematosus, foetal growth restriction, gestational diabetes, rheumatoid arthritis and obesity in pregnancy from an immunological point of view and closely examines the different pathways that result in maternal inflammation. Understanding the role of cell-free nucleic acids, as well as the biogenesis of NETs and EVs, will help us to specify their functions or targets, which seem to be important in pregnancy complications. It is still not clear whether higher concentrations of cell-free nucleic acids in the maternal circulation are the cause or consequence of various complications. Therefore, further clinical studies and, even more importantly, animal experiments that focus on the involved immunological pathways are needed.
1 | INTRODUCTION
| The immune system and nucleic acids
Nucleic acids originate in cells. During physiological and pathophysiological processes, cells can rupture and release nucleic acids into the extracellular space. Their presence in blood was first described by Mendel and Metais. 1 Cell-free nucleic acids are more fragmented than non-cell-free nucleic acids, are present as multiple types and can induce an immune response ( Figure 1 ). Two types of cell-free nucleic acids include cell-free DNA (cfDNA) bound to histones derived from the nuclei and mitochondrial DNA (mtDNA), which is not bound to histones and is structurally analogous to bacterial DNA. 2 Both types are released during cell death, including a specific type of neutrophil death termed NETosis. 3 Cell-free nucleic acids are also found in extracellular vesicles (EVs). Any cell is able to release EVs, and it has been shown that EVs may contain functional RNA, 4 mtDNA, and nuclear single-and double-stranded DNA. [5] [6] [7] The innate immune system distinguishes all antigens in a living organism, including cell-surface structures and non-cellular particles. This system is activated whenever recognized molecular patterns of infectious and non-infectious sources are detected. Under certain circumstances, cfDNA can be recognized by some receptors and may lead to autoimmune activation. 8 Immune cells gather present outside of the cell, but they do not appear to distinguish between self-and non-self-nucleic acids. Thus, these receptors might be autoactivated by their own DNA and RNA. Autoactivation may lead to several autoimmune and autoinflammatory diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), as well as pregnancy complications such as preeclampsia (PE). 16, 17 During pregnancy, the threshold for immune reactions must be adjusted to avoid rejection of an immunologically incompatible foetus. DNA from the trophoblast enters the circulation of a pregnant woman. The immune system already recognizes the foetus during the first trimester at the maternal-foetal interface of the extravillous trophoblast. It is thought that several pregnancy complications, such as PE and foetal growth restriction (FGR), might result from foetal DNA recognition by the maternal immune system. Several studies indicate that foetal DNA may induce an immune response, although the pathogenesis of these complications requires further investigation.
18,19
| Immune response to nucleic acids during pregnancy complications
A successful pregnancy requires proper conditions to assure trophoblast invasion, effective placentation and the acceptance of the foetus by the maternal immune system. However, pregnancy can be complicated by various diseases, such as PE or FGR, that prevent these conditions. Other diseases that impede pregnancy, especially SLE, RA, gestational diabetes mellitus (GDM) and obesity, affect fetomaternal cross talk. While cell-free nucleic acids appear to contribute to each of these diseases, their role has not yet been studied thoroughly. However, according to published studies, cfDNA and cfRNA could be used as markers for some of the above diseases. 20,21
| Preeclampsia
In PE, pregnant women experience symptoms such as hypertension, proteinuria and oedema; however, the aetiology of PE is unknown. It has been shown that there is a higher incidence of fetomaternal microchimerism in women with PE compared to women with normal pregnancies. This finding suggests that increased biological material of foetal origin, derived from placental cells, was found in the maternal plasma. 22 However, it is unclear whether cell-free foetal DNA (cffDNA) causes PE or if its concentration in maternal plasma increases as a consequence of other processes. No verified therapies for PE exist; only childbirth relieves the complications. 23 The crucial group of receptors related to PE is the TLR family. TLRs are present on the immune cells as well as the trophoblast of the placenta. TLRs are responsible for the protection of the foetus against pathogens. 24 After recognition of material that activates TLRs, such as single-or double-stranded RNA or DNA, the signalling pathways are initiated either dependently or independently of myeloid differentiation primary response gene-88 (MyD-88). 25 Regardless of MyD-88 dependence, the signalling pathways stimulate other molecules, including mitogen-activated protein kinase, tumour necrosis factor (TNF) receptors or interferon response factors. If the pathway depends on MyD-88, it proceeds through the intracellular signalling adapter protein Toll/IL-1 receptor, which induces TIR-domain-containing adapter-inducing interferon-b (TRIF) and results in interferon production through nuclear factor kappa-lightchain-enhancer of activated B cells (NF-jB). This activation leads to production of inflammatory cytokines and chemokines. 26 If the TLR4 activation cascade proceeds independently of MyD-88, then TLR4 activates TRIF directly to produce interferon ( Figure 3 ). 27 During normal pregnancy, this activation occurs to provide an immediate immune response against pathogens to preserve the pregnancy. However, during PE, the pathways are overactivated because TLRs sense an increase in cffDNA, and the inflammatory conditions persist throughout the entire pregnancy. During chronic inflammation that results from PE, trophoblast cells produce cytokines and chemokines. 28 The most common cytokines generated during PE are interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-1 beta (IL-1b). It is postulated that the trigger for this process is platelet-monocyte aggregate generation of soluble fms-like tyrosine kinase due to trophoblast decomposition that results from placental hypoxia. 29 This trigger leads to endothelial dysfunction and increased cell-free foetal nucleic acids, particularly mtDNA as well as nuclear DNA, messenger RNA (mRNA), and micro RNA (miRNA), in maternal plasma and the consequent immunological response towards these molecules ( Figure 4 ). [30] [31] [32] Stress conditions, such as ischaemia, lead to increased trophoblast apoptosis. TLRs induce trophoblast apoptosis and trigger the activation of caspase 3, 8, and 9. Caspase 3 is used as an apoptotic marker in PE because its level increases during the disease. 33 Caspases mediate nuclear DNA degradation and therefore contribute to increased levels of cffDNA in circulation. TLR3 and TLR7 bind to extracellular RNA and are also thought to initiate a cascade of reactions that leads to inflammation during PE. 34 Hypomethylated DNA, which is found in bacteria as well as DNA from placental cells, activates TLR9. Hypomethylated DNA is especially important during PE when the cffDNA concentration is increased in maternal plasma. This DNA has CpG motifs, meaning that there are 2 purines at the 5ꞌ end and 2 pyrimidines at the 3ꞌ end of the molecule. 35 Immunostimulation depends upon the length of hypomethylated DNA and the number of CpG pattern repetitions. Single-stranded DNA shows a higher affinity towards TLR9 than double-stranded DNA. Doublestranded DNA from the placenta is hypomethylated, while DNA from maternal tissues is hypermethylated. Placental double-stranded DNA originates from the nucleus and is bound to nuclear proteins. After TLR9 binds hypomethylated DNA, IL-6 production is activated through transcription factor NF-jB 36 ; this production can lead to preterm birth. Therefore, hypomethylated plasmatic cffDNA is considered to be a possible marker of premature labour.
According to Jakobsen et al 37 , RHD genotyping in the 25th week of pregnancy can predict preterm delivery before the 34th week. This was the first study that predicted preterm labour before the onset of symptoms. In summary, while the pathogenesis of PE remains unclear, cffDNA may be a potential predictor of the disease prior to its onset. However, the latest meta-analysis reveals that cffDNA is a relevant indicator primarily during the second trimester, and it is usually non-specific and hard to detect earlier. 39 It was observed that early-onset PE is linked to increased oxidative stress of placental trophoblast DNA and FGR. 40 Several research groups have focused on tracking cffDNA as a diagnostic marker for FGR. One study indicated that cffDNA in maternal circulation was higher in FGR pregnancies compared with normal pregnancies, and the concentration correlated with altered umbilical blood circulation. 41 Therefore, the reasons for higher cffDNA concentration could be chronic hypoxia of the placenta. On the other hand, a study reported that there were no differences between cffDNA levels in FGR compared with normal pregnancies; however, higher concentrations of cffDNA were found in pregnancies with altered uterine artery circulation with no other signs of FGR. 42 Further, this study suggested that cffDNA as well as circulation measurements could be potential predictors of FGR. The detection sensitivity of cffDNA may also differ depending on the gestational age. The disintegration of the trophoblast also contributes mtDNA to the maternal circulation, and this addition may be another possible cause or consequence of pregnancy complications (including FGR). Previous studies showed high levels of cell-free mtDNA during FGR. This change could be the result of a compensatory mechanism during placental hypoxia when more trophoblast cells release mtDNA into the circulation. 43 mtDNA is structurally similar to bacterial DNA because it is derived from saprophytic bacteria and is composed of unmethylated CpG dinucleotides. TLR9 is sensitive to and activated by unmethylated cytosine. TLR9 distribution is altered followed by the production of IL-6 through transcription factor NF-jB. 44 Therefore, higher concentrations of cell-free mtDNA in the maternal circulation during FGR could trigger inflammation. A FGR rat model demonstrated that FGR increased the levels of mtDNA as well as TLR9 expression and TNF levels in plasma. Together, these changes may induce a proinflammatory condition. 45 A recent study discussed the connection between senescent placental cells and FGR. 46 The cytotrophoblast of the placenta expands through cell fusion and this process triggers cell senescence and a consequent accumulation of damaged DNA inside the cells. These senescent cells express genes that promote apoptosis resistance. Concurrently, NF-jB is activated and increases the production of proinflammatory cytokines and chemokines to promote inflammation. The process of senescence accelerates with the length of gestation; therefore, the functions of the cytotrophoblast could be altered to promote FGR either through oxidative stress of the placenta or inflammation. 46 Both conditions contribute to hypoxia of the placenta and may induce trophoblast decomposition and increased cffDNA concentrations. Research data related to FGR are so far limited, and thus, more experiments are needed to understand its aetiology.
| SLE in pregnancy
Systemic lupus erythematosus is a chronic autoimmune disease. The symptoms appear in a variety of organs, including the joints, skin, kidneys and the nervous system. The incidence of SLE is 3-fold higher in women than in men and the specific diagnosis is SLE during pregnancy. SLE is associated with an increased rate of prenatal foetal death and miscarriage. Female SLE patients, especially older patients, can experience a host of complications, including arterial hypertension, obesity, diabetes mellitus, lupus nephritis and other renal diseases. Thus, SLE complications may lead to an adverse pregnancy outcome. 47 SLE can be distinguished from other diseases through analysis of circulating miRNA profiles, as some miRNAs are upregulated while others are downregulated. Altered miRNA increases apoptosis, the activation of cytokine production, 48 and NETosis due to oxidative stress in the mitochondria. 49 The most important disease manifestation is the production of autoantibodies against nuclear antigens, which results in inflammation. The excessive production of cytokines, chemokines and type I interferons by plasmacytoid dendritic cells is due to the presence of many complexes, including self-DNA. 50 Immunological complications in SLE patients occur due to overproduction of autoantibodies, including anti-doublestranded DNA. During pregnancy, these complications are thought to be responsible for preterm birth or foetal loss.
51
TLR7 and TLR9 are the most prominent receptors involved in the SLE autoimmune response. 52 It was previously
shown that the stimulation of TLR7 is linked with anti-RNA antibodies, whereas the stimulation of TLR9 is linked with anti-DNA antibodies. Additionally, higher TLR9 expression contributes to inflammatory reactions during SLE, especially in the kidneys during lupus nephritis 53 ;
however, the published data are heterogeneous. 54 Under normal conditions, bacteria, viruses, unmethylated CpG motifs and interferons can activate TLR7 and TLR9. This pathway is deregulated during SLE and TLR7 is upregulated and overstimulated, promoting a cellular immune response. 55 The production of double-stranded DNA antibodies increases due to greater release of cfDNA that originates from apoptotic and necrotic placental cells during
| 5 of 13 pregnancy; this cell death accelerates during SLE. 56 SLE is also associated with non-functional deoxyribonuclease I (DNase I), an enzyme involved in the digestion of cfDNA. 57 A few studies have found that high DNase I activity correlates with high levels of cfDNA. 58, 59 However, we previously hypothesized that cfDNA and cffDNA could be protected by histones from DNase I degradation, even though the activity of this enzyme is not impaired. 18 High concentrations of cfDNA, overproduction of antibodies and DNase I dysfunction contribute to gradual inflammation during pregnancy. The stimulator of interferon genes (STING) receptor has been a focus of SLE research recently. STING is an intermediate component that connects a cfDNA-sensing pathway with an immune response of an organism. A recent study by Klarquist et al showed that during inflammation, the production of type I interferon is not TLR dependent but rather requires STING and interferon regulatory factor 3 (IRF3) to induce an autoimmune response. Therefore, the authors suggested that further understanding of this pathway may develop new therapies in the area of autoimmune diseases. 60 It was reported that STING reacts to the presence of cellular DNA, CpG dinucleotides or cell-free self-DNA. Therefore, STING is activated when cffDNA fractions are increased in maternal circulation during pregnancy. This activation leads to the production of type I interferons and cytokines. The STING pathway is activated through nucleotides that attach to STING dimers to initiate the degradation of cellular components. It is directly involved in the activation of transcription factors followed by initiation of immune gene transcription ( Figure 5 ). 61 It is predicted that this transcription contributes to renal complications, preterm birth and hypertension, although additional studies will be needed to observe the connections between SLE during pregnancy and the immune system.
| Rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory disease that typically affects the lining of small joints in the hands and feet; this inflammation causes painful swelling that can eventually result in bone erosion and joint deformity. RA usually begins after the age of 40 and is much more common in women, often manifesting during their childbearing years. 62 The main markers for the detection of RA are autoantibodies to citrullinated antigens and a rheumatoid factor. Citrullination, also known as deimination, is a process of modification of arginine side chains. 63 Citrullinated proteins and immune complexes have elevated immunogenicity and arthritogenicity. The presence of these substances in arthritic joints is associated with disease severity. Several studies have demonstrated an increased amount of cfDNA in patients with RA as well as the impact of neutrophil extracellular trap (NET) formation on autoimmune conditions that lead to inflammation. 64, 65 The process commences with the presence of cfDNA, which is believed to originate from increased apoptosis during RA as well as from NETs that are present during autoimmune diseases in general. cfDNA not only activates TLRs, but it also induces the production of antibodies against citrullinated antigens and antinuclear antigens. Antibodies further activate TLRs and B cells, and this activation produces cytokines and chemokines. TNF and IL-17 particularly play a fundamental role in the processes that cause inflammation in RA patients due to microbial lipopeptides. A recent study showed that the levels of cfDNA and cfRNA in addition to antibodies against them increased during RA. 66 RA improves during pregnancy in 75%-95% of women. The improvement begins during the first trimester and continues until the last trimester of pregnancy. This improvement is caused by cytokine profiles during pregnancy, specifically an increase in Th1 and a decrease in Th2 cytokine responses, changes that are in contrast to SLE. The change in the cytokine profile means that cell-mediated immunity is suppressed and anti-inflammatory cytokines are released. RA tends to worsen again after delivery, and furthermore, new onset of RA has been observed to occur 3-5 times more during this period. 67 Population studies revealed that pregnant women suffering from RA do not have an enhanced risk of abortion, but these women do have a 1.85-to 3-fold higher risk of preterm delivery. 68 Interestingly, Khandpur et al showed that NETs are a source of citrullinated autoantigens and they effectively stimulate inflammatory responses in synovial fluid during RA. Moreover, antibodies from patients with RA target citrullinated histone 4 that is present in NETs. Neutrophils isolated from RA patients are more likely to undergo NETosis and NET overproduction after induction by lipopolysaccharides compared with neutrophils from healthy patients. This change is partially mediated by the inflammatory cytokines TNF and IL-17. After such NETosis induction, NETs promote the production of proinflammatory IL-6 and IL-8 and contribute to inflammation. 65 Therefore, serum concentrations of such NETosis-derived cytokines in suspected RA cases might serve as a new complementary diagnostic tool.
One recent study used disease-modifying anti-rheumatic drugs, also known as biological anti-inflammatory treatments, as a therapy for patients with RA. Not only did the clinical parameters of the patients improve, but cfDNA levels decreased; however, these patients were not pregnant women. 69 In connection to this study, another report examined pregnant women with RA who did not experience RA symptom improvement during pregnancy. The authors found that discontinuation of anti-inflammatory treatment before or at the beginning of the pregnancy caused disease relapse. Therefore, medication had to be applied in spite of the pregnancy. However, the resumption of medication during pregnancy did not have the same effect in all cases. 70 This finding indicates that the underlying mechanisms, possibly involving cfDNA or cffDNA, need to be understood to find more effective treatments for pregnant women experiencing RA.
| Gestational diabetes mellitus
Gestational diabetes mellitus is defined as carbohydrate intolerance detected during the first stages of pregnancy. It is caused by inefficient production of insulin. Oxidative DNA damage induces inflammation during GDM, and this damage contributes to altered anatomy and physiology of the placenta. Although GDM is not an autoimmune disorder, it is a serious pregnancy complication that can induce a strong immune response in the organism and often results in spontaneous abortion. 71 Few research groups have studied the level of cffDNA in women with GDM compared with normal pregnancies. Zamanpoor et al 72 did not observe any differences between the groups with regard to cffDNA concentrations as detected by quantitative polymerase chain reaction amplification. On the other hand, it was observed that placentas and cord blood cells from women with GDM are rich in CpG dinucleotide DNA compared with normal women. 73 This finding suggests that the level of CpG dinucleotides might be used as a potential indicator of the disease. The presence of CpG dinucleotides indicates that placental DNA is hypomethylated. Therefore, DNA emanating from apoptotic placental cells may cause inflammation through TLR9. CpG islands present in cord blood cells exposed to intrauterine hyperglycaemia can lead to macrosomia, a condition where the baby is too large for the gestational age. 74 The latest study found that there is a correlation between the concentration of cffDNA in the first trimester and gestational diabetes; therefore, cffDNA could be used as a potential predictor of the disease even though the underlying mechanism remains unknown. 75 Nonetheless, further research is required to confirm this prediction. The pathogenesis of GDM is related to obesity. Obese women are predisposed to become diabetic during gestation. Obesity itself is associated with a chronic state of mild inflammation as a result of increased TNF levels in adipose tissue 76 as well as complementary gene upregulation. 77 Therefore, during gestation, the placenta is also affected by inflammation due to placental nutrient transporter expression. The role of cell-free nucleic acids has not been deeply examined in this area but certainly it is an important factor as inflammation in general is associated with cfDNA. Thus, further studies are needed to investigate this potential role.
| Obesity in pregnancy
Obesity in pregnancy is an important factor with regard to adverse outcomes. It is usually associated with a large for gestational age foetus, infant cardiovascular problems and infant morbidity. Obesity serves as a high risk for the course and outcome of a pregnancy as well as the state of the mother. Similar to GDM, there is insufficient mitochondrial performance during obesity. Hastie and Lappas revealed that obese pregnant women had a reduced number of mitochondria through the use of mtDNA and mitochondrial complex I measurement and hypothesized that this reduction occurs due to increased placental oxidative stress, especially DNA damage. This oxidative stress is assumed to occur either through impaired transcription of genes involved in mitochondrial function (such as mitochondrial complex I) or as a result of obesity-linked cytokine induction. 78 Inflammation may also contribute towards increased apoptotic processes, with a concomitant increase in cell-free nucleic acids derived from placental cells that enter maternal circulation. Moreover, there is growing evidence that increased amounts of maternal cfDNA in the circulation of obese pregnant women may result from adipocyte necrosis or apoptosis of placental cells. 79 As cffDNA was discovered in maternal circulation, there is growing evidence that it is involved in the pathogenesis of pregnancy complications. However, as maternal cfDNA is increased due to obesity, it is more difficult to specify and quantify cffDNA as the ratio of cffDNA to cfDNA is altered. It was also demonstrated that maternal cfDNA can trigger TLR pathways and induce inflammatory processes. 80 In summary, altered mitochondrial operation and increased apoptosis may have a devastating impact on the function of the placenta, and these consequences can have further negative effects on the foetus development in obese women.
| Immune response to nucleic acids in NETs
Activated neutrophils produce NETs in the extracellular space. NETs are web-like chromatin structures that contain DNA and histones. 3 They are formed due to myriad stimuli including lipopolysaccharides and reactive oxygen species. NET formation is the initial step in neutrophil cell death. NETosis is a specific form of cell death where membranes break down, chromatin mixes with cytoplasmic proteins to form NETs, and these products, including mtDNA, are released into the extracellular space. 81 Production of NETs increases total cfDNA. NETosis occurs to defend the organism from foreign substances (for example, bacteria). During normal pregnancy, neutrophils can be easily activated. During later stages of gestation, sex hormones play a crucial role in neutrophil activation. Estradiol promotes NET formation, while progesterone prevents it. During complicated pregnancies, there are several factors that affect the formation of NETs. For example, hypoxia causes cytokine production by the trophoblast. The cytokines IL-6 and IL-8 are especially able to activate neutrophils. After initiation of NET production, the DNA that is part of NETs can interact with TLR9 similarly to cffDNA. This interaction activates dendritic cells to produce type I interferon to promote immunostimulatory effects. Peripheral blood mononuclear cells are activated through NF-jB and the production of IL-6 increases ( Figure 6 ). 82 NETs are observed in PE and SLE as they are connected to the presence of cffDNA in maternal plasma. NETs are considered to be triggers of autoinflammation as cffDNA can originate in the placental trophoblast. Gupta et al described this process as the release of particles of syncytiotrophoblast and endothelial cell origin that induces NETosis. The authors observed that the process commences after damage to the placental endothelium. DNA released from the damaged placental cells activates neutrophils. Stimulated neutrophils produce NETs, and these NETs further destroy the endothelium in a positive feedback loop to amplify pregnancy complications, increase blood coagulation and elevate the chance of thrombotic events. 83 The results of a recent study suggest that the balance of sex hormones produced by the placenta could slow down this process. 84 Neutrophil extracellular traps are especially aggressive during SLE because the body produces antibodies against all NET components due to an irregular level of cytokines. It is known that the function of DNase I is decreased during SLE, and this change may lead to inefficient degradation of NETs from the blood and prolonged impact of cfDNA on the organism. Persistent NETosis redoubles the production of interferons through a TLR9-dependent pathway that activates B cells and increases the expression of autoantibodies. 85 Recently, a study reported that there was a higher ratio of NETs to total number of neutrophils in complicated pregnancies (those with SLE or PE) compared with controls. This increase could be the result of endothelial cell apoptosis during both diseases; this cell death is associated with type I interferon mRNA expression that supports NET formation. 86 A considerably high level of NETs was also found in the placental intervillous space and contributes to inflammation of the placenta. It has not been clearly established yet whether NETs are also associated with FGR or preterm labour; however, it is an important area to be focused on in future studies.
| Immune response to EVs during various pregnancy complications
Extracellular vesicles are nanosized double-membrane particles that are released from the cell into the extracellular space. Numerous recently published papers have focused on EVs, which can exchange nucleic acid cargo as part of cell-to-cell communication. It was also demonstrated that EVs play a role in the immune system. During pregnancy, immunomodulation may result from EVs released from the placental trophoblast into the maternal circulation. 87 miRNA, mRNA, mtDNA and nuclear DNA are believed to be packed inside EVs. Therefore, EVs contribute to the amount of total cfDNA ( Figure 7 ). 4, 88 Some publications demonstrate that EVs that originate from the placental trophoblast are involved in the immune response during pregnancy through different types of human leucocyte antigens present on their surface. It is hypothesized that EVs play a role in decreasing the chance of foetal rejection. 89 mechanism of EV production in the placenta results from placental cell death. 91 The behaviour of an immune system of a pregnant woman has an impact on the innate immune system of the newborn. There is increasing, albeit insufficient, evidence that EVs, especially microvesicles, play an important role in the pathogenesis of SLE and RA in pregnant women because they serve as an important fetomaternal interface. These EVs carry proteins and DNA that could mediate proinflammatory effects or serve as potential markers of autoimmune diseases. 92 The latest research shows that EVs carry specific miRNA that activate TLR8 and subsequently stimulate the innate immune system. This research describes a new inflammatory pathway for SLE. 93 It was also reported that there are cell-free nucleic acids present in the mother's circulation, either in the form of apoptotic bodies or as so-called syncytiotrophoblast debris (EVs that contain RNA or DNA), during pregnancy. These cell-free nucleic acids are increased during FGR as well as PE. Such cell-free nucleic acids are part of the total cffDNA and contribute to the activation of the maternal immune response. 94 There is evidence that EVs cause placental inflammation during PE through inflammasome activation in trophoblast cells. 95 Similarly, specific mRNA and miRNA, located in microparticles (a subset of EVs) that originate from the placental trophoblast, were observed in maternal blood during FGR but not in the blood of healthy pregnant women. Such particles could serve as biomarkers for FGR. There have been other speculations as to the role of mRNAs and miRNA present in these particles; specific miRNA from particles may correlate to placental growth and pregnancy stage, although additional investigation is needed. 96, 97 There is a high probability that microparticles could be a form of placental-maternal communication and function in immunomodulation. Extracellular vesicles are a useful biological marker as well as an important form of therapy as they can be transported within the organism. [98] [99] [100] Currently, EVs are under investigation for potential use in the diagnosis of different pathologies, and the novel idea of a combined therapy consisting of vesicles, cytokines and different cells has been postulated. One example is the usage of EVs from mesenchymal stem cells to decrease blood pressure in mice. 101 This finding could be especially important with regard to hypertension during pregnancy complications such as PE. Another study showed that EVs derived from dendritic cells decreased inflammation by overexpression of IL-4, Il-10 and transforming growth factor beta. 102 Taylor et al 103 demonstrated that placental EVs positively affect the maternal immune response to the foetus. EVs may play an immunosuppressive or immunostimulatory role. Therefore, the function of EVs needs to be investigated not only in immunology but also in the pathogenesis of diseases both related and unrelated to pregnancy. The potential therapeutic use of EVs should be taken into consideration; however, the complexity of EVs must first be understood.
| CONCLUSIONS
cfDNA in human serum and plasma was described even before the structure of DNA was known. Unfortunately, it took decades before scientists recognized that cfDNA might be of interest for the diagnosis, monitoring and understanding of disease pathogenesis. A major breakthrough for the field of cfDNA was the discovery of foetal DNA fragments in maternal plasma. Quantification of cffDNA in plasma could be a non-invasive method for screening or monitoring several diseases, including pregnancy-related complications. This overview of the relevant published literature demonstrates that there are still discrepancies as to whether high cffDNA is a cause or a consequence of PE. Indeed, conflicting data come from animal experiments even though they are not plagued by numerous confounding variables that are present in clinical studies. cffDNA may be sequestered or protected in NETs or EVs, and so experiments with the application of truly cell-free DNA might be misleading. The physiological functions of both NETs and EVs have already been partly unveiled. If they are involved in inflammation during pregnancy diseases, it is necessary to understand the details of the underlying mechanisms to develop targeted effective therapies. Despite years of research, the aetiology of most pregnancy complications remains unknown and the pathogenesis is still largely unexplained. Last but not least, in vivo cfDNA is not necessarily "cell free" as it is recognized by TLR9 and other cellular DNA sensing receptors. This concept may shift future research away from strictly focusing on the diagnostic value of extracellular DNA to its potential involvement in the pathogenesis of pregnancy-related complications.
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